Tonix Pharmaceuticals Holding Corp (NASDAQ:TNXP) currently has a daily average trading volume of 1.61M but it saw 2701273 shares traded in last market. With a market cap of 61.28M USD, the company’s current market price of $10.96 came rising about 40.51 while comparing to the previous closing price of $7.80. In past 52 weeks, the stock remained buoying in the range of price level as high as $1216.00 and as low as $6.76.
Taking a look at 20-day trading activity of Tonix Pharmaceuticals Holding Corp (TNXP) gives us an average price of $10.23, while its current price level is -99.10% below from 52-week high level whereas it is 62.13% above from lowest level seen by the stock during that period. Simple moving average of 50 days or SMA-50 of the stock’s closing price is $24.16 while that of 200 days or SMA-200 reads an average of $75.07. A closer look into the stock’s movement over the week reveals that its volatility is standing at 17.06% during that period while stretching the period over a month that increases to 17.31%. It is also necessary to take a look into other indicators of a stock too, to get a better idea about its price movement. And in doing so, we find stock’s 14-day relative strength index (RSI) standing at 42.25 which implies that the stock is in neutral territory.
ROTH Capital upgraded its recommendation for the stock as a “Buy” from “Neutral” on April 18, 2019 while assigning a price target of $4. ROTH Capital issued its recommendations for the stock as it upgraded the price target for the stock is $6.
Over the week, TNXP’s stock price is moving 30.01% up while it is -43.77% when we observe its performance for the past one month. Year-to-date it is -66.77% down and over the past year, the stock is showing a downside performance of -99.07%.
The company is expected to be releasing its next quarterly report in April, for which analysts forecasted an EPS of 0 while estimate for next year EPS is 0. In next quarter, company is expected to be making quarterly sales of $4.2M as analysts are expecting the sales for current fiscal year at $12.95M and seeing the company making $17.25M in sales next year. Moreover, analysts are in estimates of $3.35M for current-quarter revenue.
Currently, Tonix Pharmaceuticals Holding Corp’s total number of outstanding shares is 155.63M with 0.00% of that held by the insiders while 3.32% of its common stock has been owned by the institutions. Company’s return on investment (ROI) stands at -169.47% and return on equity (ROE) at -138.69%. Stock’s beta reads 2.24. Stock has a price to book (P/B) ratio of 22.98 while price to sale or P/S ratio amounts to 5.43. Its return on asset (ROA) is -115.46% on average.
